Literature DB >> 36227429

Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection.

Chang-Hai Liu1,2, Wei Jiang1,2, Dong-Bo Wu1,2, Qing-Min Zeng1,2, You-Juan Wang3, Hong Tang4,5.   

Abstract

BACKGROUND: The association between hepatitis B and concomitant diseases, such as fatty liver, T2DM, MetS, and Hp infection, remains unclear. AIM: The present study was to illustrate the association and explore the co-contribution on abnormal transaminase and progression of liver stiffness.
METHODS: A total of 95,998 participants underwent HBsAg screening in West China Hospital from 2014 to 2017. Multivariable logistic regression was used to determine the adjusted odds ratios.
RESULTS: The prevalence of HBsAg-positive rate was 8.30% of our included study population. HBsAg positive was associated with negative risk of fatty liver (odds ratio [OR] 0.71, 95% confidence interval [CI] 0.65-0.78, p < 0.001) and MetS (OR 0.74, 95% CI 0.67-0.84, p < 0.001), and with positive risk of Hp infection (OR 1.09, 95% CI 1.02-1.17, p = 0.012) and T2DM (OR 1.18, 95% CI 1.01-1.40, p = 0.043). Besides, HBsAg-positive patients with T2DM had higher risk of elevated ALT (OR 2.09, 95% CI 1.69-2.83, p < 0.001 vs OR 1.59, 95% CI 1.51-1.68, p < 0.001), AST (OR 2.69, 95% CI 1.98-3.65, p < 0.001 vs OR 1.89, 95% CI 1.76-2.02, p < 0.001) than HBV alone. In addition to HBV, T2DM also can increase the risk of liver fibrosis (OR 3.23, 95% CI 1.35-7.71, p = 0.008) and cirrhosis (OR 4.31, 95% CI 1.41-13.20, p = 0.010).
CONCLUSION: Hepatitis B patients have a lower risk of fatty liver and MetS, and a higher risk of T2DM and Hp infection. Besides, T2DM might be possibly associated with abnormal liver transaminase and fibrosis progression in HBsAg-positive patients.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Abnormal liver transaminase; Coexisting diseases; HBV; Liver stiffness; Metabolic syndrome; Multivariable logistic regression; Type 2 diabetes mellitus

Year:  2022        PMID: 36227429     DOI: 10.1007/s10620-022-07695-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  51 in total

Review 1.  Hepatitis B virus infection.

Authors:  Man-Fung Yuen; Ding-Shinn Chen; Geoffrey M Dusheiko; Harry L A Janssen; Daryl T Y Lau; Stephen A Locarnini; Marion G Peters; Ching-Lung Lai
Journal:  Nat Rev Dis Primers       Date:  2018-06-07       Impact factor: 52.329

2.  Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

Authors:  Raluca Pais; Elena Rusu; Diana Zilisteanu; Alexandra Circiumaru; Laurentiu Micu; Mihai Voiculescu; Thierry Poynard; Vlad Ratziu
Journal:  Eur J Intern Med       Date:  2014-12-29       Impact factor: 4.487

3.  Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

Authors:  Gioacchino Leandro; Alessandra Mangia; Jason Hui; Paolo Fabris; Laura Rubbia-Brandt; Guido Colloredo; Luigi E Adinolfi; Tarik Asselah; Julie R Jonsson; Antonina Smedile; Norah Terrault; Valerio Pazienza; Maria Teresa Giordani; Emiliano Giostra; Aurelio Sonzogni; Giuseppe Ruggiero; Patrick Marcellin; Elizabeth E Powell; Jacob George; Francesco Negro
Journal:  Gastroenterology       Date:  2006-05       Impact factor: 22.682

4.  Hepatitis B virus infection and fatty liver in the general population.

Authors:  Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Winnie Chiu-Wing Chu; Angel Mei-Ling Chim; Arlinking Ong; David Ka-Wai Yeung; Karen Kar-Lum Yiu; Shirley Ho-Ting Chu; Hoi-Yun Chan; Jean Woo; Francis Ka-Leung Chan; Henry Lik-Yuen Chan
Journal:  J Hepatol       Date:  2011-10-23       Impact factor: 25.083

5.  Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors.

Authors:  Dandan Peng; Ying Han; Huiguo Ding; Lai Wei
Journal:  J Gastroenterol Hepatol       Date:  2008-07       Impact factor: 4.029

6.  Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors.

Authors:  Man-Man Wang; Gong-Sui Wang; Feng Shen; Guang-Yu Chen; Qin Pan; Jian-Gao Fan
Journal:  Dig Dis Sci       Date:  2014-05-18       Impact factor: 3.199

Review 7.  Chronic hepatitis B virus infection.

Authors:  Wai-Kay Seto; Ying-Ru Lo; Jean-Michel Pawlotsky; Man-Fung Yuen
Journal:  Lancet       Date:  2018-11-24       Impact factor: 79.321

8.  Chronic hepatitis B virus infection status is more prevalent in patients with type 2 diabetes.

Authors:  Jun Lu; Xuhong Hou; Hong Tu; Zhenghao Tang; Yongbing Xiang; Yuqian Bao; Jianren Gu; Weiping Jia
Journal:  J Diabetes Investig       Date:  2017-03-13       Impact factor: 4.232

9.  Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study.

Authors:  Yongze Li; Di Teng; Xiaoguang Shi; Guijun Qin; Yingfen Qin; Huibiao Quan; Bingyin Shi; Hui Sun; Jianming Ba; Bing Chen; Jianling Du; Lanjie He; Xiaoyang Lai; Yanbo Li; Haiyi Chi; Eryuan Liao; Chao Liu; Libin Liu; Xulei Tang; Nanwei Tong; Guixia Wang; Jin-An Zhang; Youmin Wang; Yuanming Xue; Li Yan; Jing Yang; Lihui Yang; Yongli Yao; Zhen Ye; Qiao Zhang; Lihui Zhang; Jun Zhu; Mei Zhu; Guang Ning; Yiming Mu; Jiajun Zhao; Weiping Teng; Zhongyan Shan
Journal:  BMJ       Date:  2020-04-28

10.  Association between self-monitoring of blood glucose and hepatitis B virus infection among people with diabetes mellitus: a cross-sectional study in Gansu Province, China.

Authors:  Bingfeng Han; Wu Liu; Shubo Yang; Shuai Wang; Juan Du; Yaqiong Liu; Fuqiang Cui
Journal:  BMJ Open       Date:  2021-10-07       Impact factor: 3.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.